Microba Life Sciences Ltd
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the huma… Read more
Microba Life Sciences Ltd - Asset Resilience Ratio
Microba Life Sciences Ltd (MAP) has an Asset Resilience Ratio of 6.02% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Microba Life Sciences Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Microba Life Sciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$2.71 Million | 5.72% |
| Short-term Investments | AU$138.64K | 0.29% |
| Total Liquid Assets | AU$2.85 Million | 6.02% |
Asset Resilience Insights
- Limited Liquidity: Microba Life Sciences Ltd maintains only 6.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Microba Life Sciences Ltd Industry Peers by Asset Resilience Ratio
Compare Microba Life Sciences Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 14.36% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Microba Life Sciences Ltd (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Microba Life Sciences Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 6.02% | AU$2.85 Million | AU$47.44 Million | -1.60pp |
| 2023-12-31 | 7.61% | AU$4.42 Million | AU$58.04 Million | -19.28pp |
| 2022-12-31 | 26.90% | AU$12.63 Million | AU$46.95 Million | +25.86pp |
| 2021-12-31 | 1.04% | AU$408.88K | AU$39.48 Million | +0.49pp |
| 2020-12-31 | 0.54% | AU$100.60K | AU$18.49 Million | +0.08pp |
| 2019-12-31 | 0.46% | AU$49.77K | AU$10.81 Million | -- |
| 2018-12-31 | 0.00% | AU$0.00 | AU$13.99 Million | -- |